【摘要】 目的评价Ⅲ、Ⅳ级脑胶质瘤术后放疗联合替莫唑胺化疗的近期疗效。方法回顾分析2011年1月至2013年10月收治的52例Ⅲ、Ⅳ级脑胶质瘤术后放疗或放化疗患者的临床资料,其中单纯放疗19例,放疗联合替莫唑胺化疗33例。分析患者近期疗效。结果随访率100%,随访时间满1、2年样本数分别为22、7例。1、2年总生存率分别为44.0%、13.46%。单因素分析显示:手术切除程度、术前有无癫痫、是否同期化疗均为影响患者生存的因素(P=0.000、0.013、0.003)。多因素分析显示:肿瘤切除程度、术前有无癫痫发作、放疗是否联合替莫唑胺化疗、化疗周期数是影响患者生存预后的独立影响因素(P=0.001、0.018、0.028、0.006)。结论Ⅲ、Ⅳ级脑胶质瘤术后患者放疗联合替莫唑胺化疗可取得较好疗效,同时肿瘤切除程度、术前有无癫痫发作、放疗联合替莫唑胺化疗及化疗周期数是影响恶性胶质瘤患者长期生存的重要因素。更多还原

【Abstract】 Objective To evaluate the short-term therapeutic effects of postoperative radiotherapy combined with temozolomide chemotherapy on grade Ⅲ or Ⅳ brain glioma. Methods The clinical data about 52 patients with grade Ⅲ or Ⅳbrain glioma who were admitted and treated in our hospital from January 2011 to October 2013 were retrospectively analyzed,in which 19 patients were treated by simple radiotherapy and 33 patients were treated by radiotherapy combined with temozolomide chemotherapy. The short-term therapeutic effects were observed and compared between two groups. Results The follow-up rate was 100%. The 22 patients were followed up for at least 1 year,and 7 patients were followed up over 2 years.The 1-year and 2-year overall survival rates were 44. 0% and 13. 46%,respectively. The single factor analysis showed that the surgical ablation extent of tumor,with or without epilepsy seizures before surgery,radiotherapy combined with synchronization chemotherapy were main factors influencing survival time of patients( P < 0. 01). The multiple factor analysis showed that the surgical ablation extent of tumor,with or without epilepsy seizures before surgery,radiotherapy combined with synchronization temozolomide chemotherapy and chemotherapy cycle number were independent influencing factors on the survival time and prognosis of patients.( P < 0. 05 or P < 0. 01). Conclusion The postoperative radiotherapy combined with temozolomide chemotherapy has better therapeutic effects on grade Ⅲ/Ⅳ brain glioma,moreover,the surgical ablation extent of tumor,with or without epilepsy seizures before surgery,radiotherapy combined with synchronization chemotherapy and chemotherapy cycle number are important influencing factors on the survival time and prognosis of patients with malignant brain glioma.更多还原